Savara将1.3亿美元股权定价为4.20美元

2025-10-30 15:35

Clinical stage biopharmaceutical company focused on rare respiratory diseases—Savara (SVRA) priced an underwritten public offering of ~23.81M shares at a price of $4.20 per share.
Total gross proceeds of $130M are expected
The underwriters have a 30-day option to purchase up to an additional ~4.64M shares.
The offering is expected to close on October 31, 2025.
The proceeds will be used for general corporate purposes, which include the funding of clinical development of and pursuing regulatory approval for MOLBREEVI*, investing in commercialization infrastructure and supply, commercial launch preparation activities in the U.S. and EU, and general and administrative expenses.

More on Savara